WallStSmart

Co-Diagnostics, Inc. Common Stock (CODX)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 3581458% more annual revenue ($25.84B vs $721,390). SYK leads profitability with a 14.4% profit margin vs 0.0%. SYK earns a higher WallStSmart Score of 67/100 (B-).

CODX

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 1/9Altman Z: -7.49

SYK

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 8.0Value: 4.7Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CODX.

SYKSignificantly Overvalued (-19.9%)

Margin of Safety

-19.9%

Fair Value

$229.73

Current Price

$275.56

$45.83 premium

UndervaluedFair: $229.73Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CODX3 strengths · Avg: 9.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.149/10

Conservative balance sheet, low leverage

EPS GrowthGrowth
30.8%8/10

Earnings expanding 30.8% YoY

SYK4 strengths · Avg: 8.3/10
Market CapQuality
$105.70B9/10

Large-cap with strong market position

Operating MarginProfitability
27.0%8/10

Strong operational efficiency at 27.0%

EPS GrowthGrowth
44.1%8/10

Earnings expanding 44.1% YoY

Free Cash FlowQuality
$1.06B8/10

Generating 1.1B in free cash flow

Areas to Watch

CODX4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
2.0%4/10

2.0% revenue growth

Market CapQuality
$8.31M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

SYK2 concerns · Avg: 3.5/10
P/E RatioValuation
28.0x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CODX

The strongest argument for CODX centers on Price/Book, Debt/Equity, EPS Growth.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap, Operating Margin, EPS Growth. PEG of 1.15 suggests the stock is reasonably priced for its growth.

Bear Case : CODX

The primary concerns for CODX are Revenue Growth, Market Cap, Profit Margin.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

CODX carries more volatility with a beta of 2.88 — expect wider price swings.

SYK is growing revenue faster at 9.4% — sustainability is the question.

SYK generates stronger free cash flow (1.1B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (67/100 vs 33/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Co-Diagnostics, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

Co-Diagnostics, Inc., a molecular diagnostic company, develops, manufactures, and sells reagents used for diagnostic tests that function by detecting and / or analyzing nucleic acid molecules. The company is headquartered in Salt Lake City, Utah.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?